{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:51:16Z","timestamp":1791697876921,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"French Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>A major issue in the management of craniopharyngioma-related obesity (CRO) is the ineffectiveness of the current therapeutic approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study the efficacy of glucagon-like peptide-1 analogs compared with placebo in adults with obesity CRO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A double-blind multicenter superiority randomized clinical in trial in two parallel arms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Eleven French University Hospital Centers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults with CRO (body mass index &amp;gt; 30 kg\/m\u00b2) without the sign of recurrence of craniopharyngioma in the past year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Exenatide or placebo injected subcutaneously twice a day during 26 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The primary outcome was the mean change in body weight at week 26 in the intention-to-treat population. Secondary outcomes were eating behavior, calories intake, energy expenditure, cardiovascular, metabolic risk factor, quality of life, and the tolerance profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At week 26, weight decreased from baseline by a mean of \u22123.8 (SD 4.3) kg for exenatide and \u22121.6 (3.8) kg for placebo. The adjusted mean treatment difference was \u22123.1 kg (95% confidence interval [CI] \u22127.0 to 0.7, P = 0.11). Results were compatible with a higher reduction of hunger score with exenatide compared with placebo (estimated treatment difference in change from baseline to week 26: \u22122.3, 95% CI \u22124.5 to \u22120.2), while all other outcomes did not significantly differ between groups. Adverse events were more common with exenatide versus placebo, and occurred in, respectively, 19 (95%) participants (108 events) and 14 (70%) participants (54 events).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Combined with intensive lifestyle interventions, a 26-week treatment with exenatide was not demonstrated superior to placebo to treat craniopharyngioma-related obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae024","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T06:34:27Z","timestamp":1709793267000},"page":"257-265","source":"Crossref","is-referenced-by-count":28,"title":["Impact of exenatide on weight loss and eating behavior in adults with craniopharyngioma-related obesity: the CRANIOEXE randomized placebo-controlled trial"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7399-1330","authenticated-orcid":false,"given":"Blandine","family":"Gatta-Cherifi","sequence":"first","affiliation":[{"name":"CHU Bordeaux, Groupe Hospitalier Sud, Hopital Haut L\u00e9v\u00eaque Service Endocrinologie, Diab\u00e9tologie, Nutrition , 33604 Pessac , France"},{"name":"Neurocentre Magendie, Equipe \u00abphysiopathologie de la balance \u00e9nerg\u00e9tique et ob\u00e9sit\u00e9\u00bb INSERMU1215, Universit\u00e9 de Bordeaux , 3300 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamel","family":"Mohammedi","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Groupe Hospitalier Sud, Hopital Haut L\u00e9v\u00eaque Service Endocrinologie, Diab\u00e9tologie, Nutrition , 33604 Pessac , France"},{"name":"Universit\u00e9 de Bordeaux, Inserm, Biology of Cardiovascular Diseases , 33000 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanguy","family":"Cariou","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Service d\u2019information m\u00e9dicale , Bordeaux 33000 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-6331","authenticated-orcid":false,"given":"Christine","family":"Poitou","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, Centre de r\u00e9f\u00e9rence Maladies Rares (PRADORT, Syndrome de Prader-Willi et autres formes rares d\u2019ob\u00e9sit\u00e9 avec troubles du comportement alimentaire), Service de Nutrition, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , 75013 Paris , France"},{"name":"Sorbonne Universit\u00e9, INSERM, NutriOmics Research Unit , 75013 Paris , France"},{"name":"ENDO-ERN (European Reference Network on Rare Endocrine Conditions)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8462-7753","authenticated-orcid":false,"given":"Philippe","family":"Touraine","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Reproductive Medicine, Centre de Maladies Endocriniennes Rares de la Croissance et du D\u00e9veloppement, H\u00f4pital Universitaire Piti\u00e9 Salp\u00eatri\u00e8re-Charles Foix, Sorbonne Universit\u00e9, Facult\u00e9 de m\u00e9decine , 75013 Paris Cedex 13 , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, \u201cGroupement Hospitalier Est,\u201d F\u00e9d\u00e9ration d\u2019Endocrinologie, Centre de R\u00e9f\u00e9rence des Maladies Rares de L\u2019hypophyse HYPO , 69677 Bron , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-6691","authenticated-orcid":false,"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Marseille (AP-HM), Department of Endocrinology, H\u00f4pital de la Conception, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019hypophyse HYPO , 13005 Marseille , France"},{"name":"Aix-Marseille Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1251, Marseille Medical Genetics (MMG), Institut Marseille Maladies Rares (MarMaRa) , 13005 Marseille , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-5722","authenticated-orcid":false,"given":"Philippe","family":"Chanson","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Saclay, INSERM Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de paris, Hopital Bic\u00eatre, Service d\u2019endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Illouz","sequence":"additional","affiliation":[{"name":"CHU Angers, D\u00e9partement d\u2019Endocrinology, Centre de R\u00e9f\u00e9rence des Maladies Rares de L\u2019hypophyse , 49000 Angers , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-448X","authenticated-orcid":false,"given":"Solange","family":"Grunenwald","sequence":"additional","affiliation":[{"name":"CHU Toulouse, Service d\u2019endocrinologie, Centre de R\u00e9f\u00e9rence des Maladies Rares de L\u2019hypophyse, Centre de r\u00e9f\u00e9rence Maladies Rares PRADORT , 31000 Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chabre","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Grenoble Alpes, UMR 1292 INSERM-CEA-UGA, Endocrinologie CHU Grenoble Alpes , 38000 Grenoble , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Sonnet","sequence":"additional","affiliation":[{"name":"CHRU Brest, Service diab\u00e9tologie-endocrinologie , 29000 Brest , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-0030","authenticated-orcid":false,"given":"Thomas","family":"Cuny","sequence":"additional","affiliation":[{"name":"Aix-Marseille Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), U1251, Marseille Medical Genetics (MMG), Institut Marseille Maladies Rares (MarMaRa) , 13005 Marseille , France"},{"name":"Universit\u00e9 Paris Saclay, INSERM Physiologie et Physiopathologie Endocriniennes, Assistance Publique-H\u00f4pitaux de paris, Hopital Bic\u00eatre, Service d\u2019endocrinologie et des Maladies de la Reproduction, Centre de R\u00e9f\u00e9rence des Maladies Rares de l\u2019Hypophyse , 94275 Le Kremlin-Bic\u00eatre , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jer\u00f4me","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, H\u00f4pital Cochin, Reference and Competence Center Rare Adrenal Diseases and for Rare Pituitary Diseases, Assistance Publique-H\u00f4pitaux de Paris , 75014 Paris , France"},{"name":"Universit\u00e9 Paris Cit\u00e9, CNRS UMR8104, INSERM U1016, Institut Cochin , 75014 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Czernichow","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 , Paris , France"},{"name":"AP-HP, Service de Nutrition, Centre Sp\u00e9cialis\u00e9 Ob\u00e9sit\u00e9, H\u00f4pital Europ\u00e9en Georges Pompidou , 75015 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5844-1886","authenticated-orcid":false,"given":"Eric","family":"Frison","sequence":"additional","affiliation":[{"name":"Assistance Publique-H\u00f4pitaux de Paris, Centre de r\u00e9f\u00e9rence Maladies Rares (PRADORT, Syndrome de Prader-Willi et autres formes rares d\u2019ob\u00e9sit\u00e9 avec troubles du comportement alimentaire), Service de Nutrition, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , 75013 Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-3306","authenticated-orcid":false,"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, Groupe Hospitalier Sud, Hopital Haut L\u00e9v\u00eaque Service Endocrinologie, Diab\u00e9tologie, Nutrition , 33604 Pessac , France"},{"name":"Neurocentre Magendie, Equipe \u00abphysiopathologie de la balance \u00e9nerg\u00e9tique et ob\u00e9sit\u00e9\u00bb INSERMU1215, Universit\u00e9 de Bordeaux , 3300 Bordeaux , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"3","key":"2024042910113077600_lvae024-B1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ecl.2020.05.009","article-title":"Management of hypothalamic obesity","volume":"49","author":"M\u00fcller","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2024042910113077600_lvae024-B2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/er.2018-00017","article-title":"Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: a systematic review","volume":"40","author":"van Iersel","year":"2019","journal-title":"Endocr Rev"},{"issue":"2","key":"2024042910113077600_lvae024-B3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"23","author":"Roth","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2024042910113077600_lvae024-B4","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41366-021-01043-6","article-title":"Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist","volume":"46","author":"Shoemaker","year":"2022","journal-title":"Int J Obes (Lond)"},{"issue":"9701","key":"2024042910113077600_lvae024-B5","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"2024042910113077600_lvae024-B6","first-page":"e4","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"385","author":"Wilding","year":"2021","journal-title":"Reply. N Engl J Med"},{"issue":"10","key":"2024042910113077600_lvae024-B7","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"7","key":"2024042910113077600_lvae024-B8","doi-asserted-by":"crossref","first-page":"e0133977","DOI":"10.1371\/journal.pone.0133977","article-title":"Eating behaviour in the general population: an analysis of the factor structure of the German version of the three-factor-eating-questionnaire (TFEQ) and its association with the body mass index","volume":"10","author":"L\u00f6ffler","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"2024042910113077600_lvae024-B9","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1210\/jc.2007-0826","article-title":"Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes","volume":"92","author":"Danielsson","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042910113077600_lvae024-B10","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1210\/jc.2002-030003","article-title":"Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial","volume":"88","author":"Lustig","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024042910113077600_lvae024-B11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-277X.2012.01275.x","article-title":"A reduced-energy intake, well-balanced diet improves weight control in children with Prader-Willi syndrome","volume":"26","author":"Miller","year":"2013","journal-title":"J Hum Nutr Diet"},{"issue":"12","key":"2024042910113077600_lvae024-B12","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1210\/jc.2016-2126","article-title":"Diazoxide in children with obesity after hypothalamic-pituitary lesions: a randomized, placebo-controlled trial","volume":"101","author":"Brauner","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2024042910113077600_lvae024-B13","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000496564","article-title":"Hypothalamic obesity: prologue and promise","volume":"91","author":"Abuzzahab","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"2024042910113077600_lvae024-B14","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.metabol.2016.03.009","article-title":"Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study","volume":"65","author":"Farr","year":"2016","journal-title":"Metab Clin Exp."},{"issue":"12","key":"2024042910113077600_lvae024-B15","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.2337\/db14-0849","article-title":"GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans","volume":"63","author":"van Bloemendaal","year":"2014","journal-title":"Diabetes"},{"issue":"1-2","key":"2024042910113077600_lvae024-B16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1515\/jpem-2014-0415","article-title":"Eating behavior, weight problems and eating disorders in 101 long-term survivors of childhood-onset craniopharyngioma","volume":"28","author":"Hoffmann","year":"2015","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"2024042910113077600_lvae024-B17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/ijpo.12131","article-title":"Effects of exenatide on weight and appetite in overweight adolescents and young adults with Prader-Willi syndrome","volume":"12","author":"Salehi","year":"2017","journal-title":"Pediatr Obes"},{"issue":"3","key":"2024042910113077600_lvae024-B18","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"12","key":"2024042910113077600_lvae024-B19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"2024042910113077600_lvae024-B20","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1210\/jc.2003-032209","article-title":"Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma","volume":"90","author":"Goldstone","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2024042910113077600_lvae024-B21","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/BF00281984","article-title":"An hypothesis on the aetiology of obesity: dysfunction of the central nervous system as a primary cause","volume":"28","author":"Jeanrenaud","year":"1985","journal-title":"Diabetologia"},{"issue":"7","key":"2024042910113077600_lvae024-B22","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1210\/jc.2002-021545","article-title":"Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes","volume":"88","author":"Kolterman","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2024042910113077600_lvae024-B23","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/oby.21493","article-title":"A 52-week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity","volume":"24","author":"Lomenick","year":"2016","journal-title":"Obesity"},{"issue":"4","key":"2024042910113077600_lvae024-B24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/87551225221092681","article-title":"Once-weekly semaglutide for weight management: a clinical review","volume":"38","author":"Fornes","year":"2022","journal-title":"J Pharm Technol"},{"issue":"4","key":"2024042910113077600_lvae024-B25","first-page":"1","article-title":"Semaglutide for treating obesity induced by craniopharyngioma resection: a successful case study","volume":"1","author":"Sciacovelli","year":"2023","journal-title":"JCEM Case Rep"},{"issue":"4","key":"2024042910113077600_lvae024-B26","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1210\/er.2006-0002","article-title":"Craniopharyngiomas","volume":"27","author":"Karavitaki","year":"2006","journal-title":"Endocr Rev"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae024\/56946998\/lvae024.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/4\/257\/57305982\/lvae024.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/190\/4\/257\/57305982\/lvae024.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T06:12:04Z","timestamp":1714371124000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/190\/4\/257\/7623657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,3,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae024","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,3,12]]}}}